Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome
作者： J Remon , T Morán , N Reguart , M Majem , E Carcereny
DOI: 10.1016/J.CTRV.2014.03.006
关键词: Oncology 、 Medicine 、 Epidermal growth factor receptor tyrosine kinase 、 First line treatment 、 Progression-free survival 、 Chemotherapy 、 Standard treatment 、 Lung cancer 、 Egfr tki 、 Internal medicine 、 Non small cell
摘要: First line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is the standard treatment in advanced EGFR-mutant Non Small Cell Lung Cancer (NSCLC) patients, with an improvement response rate, progression free survival, and quality of life compared upfront chemotherapy. However, real world, EGFR mutation results often return positive once chemotherapy has been started. Different clinical strategies have tested this situation: reserve TKI until tumor become resistant beyond chemotherapy, stop switch to TKI, introduce as a maintenance treatment, or combined such intercalated concurrent plus In review, we aim summarize evidence first strategy discuss potential options sequence patients.
elsevier.com
sci-hub.se 参考文章(88)
Wenhua Liang, Xuan Wu, Wenfeng Fang, Yuanyuan Zhao, Yunpeng Yang, Zhihuang Hu, Cong Xue, Jing Zhang, Jianwei Zhang, Yuxiang Ma, Ting Zhou, Yue Yan, Xue Hou, Tao Qin, Xiaoxiao Dinglin, Ying Tian, Peiyu Huang, Yan Huang, Hongyun Zhao, Li Zhang, Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0085245
Makoto Maemondo, Yuji Minegishi, Akira Inoue, Kunihiko Kobayashi, Masao Harada, Shoji Okinaga, Naoto Morikawa, Satoshi Oizumi, Tomoaki Tanaka, Hiroshi Isobe, Shoji Kudoh, Koichi Hagiwara, Toshihiro Nukiwa, Akihiko Gemmah, First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study Journal of Thoracic Oncology. ,vol. 7, pp. 1417- 1422 ,(2012) , 10.1097/JTO.0B013E318260DE8B
L.E.L. Hendriks, E.F. Smit, B.A.H. Vosse, W.W. Mellema, D.A.M. Heideman, G.P. Bootsma, M. Westenend, C. Pitz, G.J. de Vries, R. Houben, K. Grünberg, M. Bendek, E.-J.M. Speel, A.-M.C. Dingemans, EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases? Lung Cancer. ,vol. 84, pp. 86- 91 ,(2014) , 10.1016/J.LUNGCAN.2014.01.006
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou, Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. International Journal of Cancer. ,vol. 131, ,(2012) , 10.1002/IJC.27396
Liping Li, Hong Wang, Eddy S. Yang, Carlos L. Arteaga, Fen Xia, Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Research. ,vol. 68, pp. 9141- 9146 ,(2008) , 10.1158/0008-5472.CAN-08-1127
S Gahr, R Stoehr, E Geissinger, J H Ficker, W M Brueckl, A Gschwendtner, S Gattenloehner, F S Fuchs, C Schulz, R J Rieker, A Hartmann, P Ruemmele, W Dietmaier, EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice British Journal of Cancer. ,vol. 109, pp. 1821- 1828 ,(2013) , 10.1038/BJC.2013.511
Yiliang Zhang, Yihua Sun, Lei Wang, Ting Ye, Yunjian Pan, Haichuan Hu, Yongfu Yu, Yanyan Song, Naiqing Zhao, Haiquan Chen, David Garfield, Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials OncoTargets and Therapy. ,vol. 6, pp. 1771- 1777 ,(2013) , 10.2147/OTT.S54502
S.J. Park, H.T. Kim, D.H. Lee, K.P. Kim, S.-W. Kim, C. Suh, J.S. Lee, Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer. ,vol. 77, pp. 556- 560 ,(2012) , 10.1016/J.LUNGCAN.2012.05.092
Frédérique Nowak, Fabien Calvo, Jean-Charles Soria, Europe Does It Better: Molecular Testing across a National Health Care System—The French Example American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 33, pp. 332- 337 ,(2013) , 10.1200/EDBOOK_AM.2013.33.332
Kazutoshi Isobe, Yoshinobu Hata, Naobumi Tochigi, Kyohei Kaburaki, Hiroshi Kobayashi, Takashi Makino, Hajime Otsuka, Fumitomo Sato, Fumiaki Ishida, Naoshi Kikuchi, Nao Hirota, Keita Sato, Go Sano, Keishi Sugino, Susumu Sakamoto, Yujiro Takai, Kazutoshi Shibuya, Akira Iyoda, Sakae Homma, Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation Journal of Thoracic Oncology. ,vol. 9, pp. 483- 487 ,(2014) , 10.1097/JTO.0000000000000125